Ключевые слова:
semizlik, saqlangan chiqarish fraksiyali yurak yetishmovchiligi, inkretinlar, semaglutid, tirzepatid, GLP-1 retseptorlari agonistlari, STEP-HFpEF, SUMMIT.Библиографические ссылки
1. Abdaliyeva, M. P., Adilbekova, D. B., Akhrorov, A. A., & Toshpulatov, S. S. (2025). Morphogenesis of the vascular structures of the gastric wall of offspring born with diabetes in postnatal ontogenesis.
2. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi:10.1056/NEJMoa2107038.
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26–36. doi:10.1056/NEJMoa2416394. PMID: 40353578.
4. Ahrorov A.A., Baxrixonova O.M., Yakubova R.Sh., Nizomiddinova D.A. (2026). Arterial gipertoniya kasalligida endothelial disfunksiyaning tomir devori morfologik va immunogistokimyoviy o‘zgarishlariga ta’siri (Adabiyotlar sharhi). Yosh olimlar tibbiyot jurnali, 1(18(06), 204-208.
5. Adilbekova, D. B., Xojaniyazova, A. Z., Ahrorov, A. A., & Toshpo‘Latov, S. S. (2025). Qandli diabet bilan xastalangan ota va onalardan tug ‘ilgan avlodlar yurak qorinchalarining devoridagi morfometrik o ‘zgarishlar. International scientific journal of Biruni, 4(2), 112-118.
6. Adilbekova, D. B., Xojaniyazova, A. Z., Toshpulatov, S. S., & Ahrorov, A. A. (2026). Sexual dimorphism in the cardiac morphological response to maternal diabetes: a comparative histological and morphometric study. Zamonaviy tibbiyot jurnali (Журнал современной медицины), 12(1), 13-22.
7. Borlaug BA, Zile MR, Kramer CM, et al. Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial. J Am Coll Cardiol. 2025;86(4):242–255. doi: 10.1016/j.jacc.2025.04.059. PMID: 40701 669.
8. Borlaug BA, Zile MR, Kramer CM, et al. Effects of tirzepatide in obesity-related HFpEF by sex: a prespecified secondary analysis from the SUMMIT trial. JACC Heart Fail. 2026. doi: 10.1016/j.jchf.2026. 103218. PMID: 42417681.
9. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437): 1635–1648. doi:10.1016/S0140-6736(24)00469-0. PMID: 38599221.
10. Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024; 404(10454):773–786. doi:10.1016/S0140-6736(24 )01498-3. PMID: 39181597.
11. European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy). 6 June 2025. https://www.ema.europa.eu/en /news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy
12. Galindo RJ, Cheng AYY, Longuet C, et al. Insights into the mechanism of action of tirzepatide: a narrative review. Diabetes Ther. 2025. doi:10.1007/ s13300-025-01804-w.
13. Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024. doi:10.1001/jamaophthalmol.2024. 2296.
14. He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022. doi:10.1001/jama-internmed.2022.0338. PMID: 35344001.
15. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17): e263–e421. doi: 10.1016/j.jacc.2021.12.012.
16. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/ NEJMoa2206038. PMID: 35658024.
17. Jung MH, Shin MS. Obesity-related heart failure with preserved ejection fraction: diagnostic and therapeutic challenges. Korean J Intern Med. 2023;38(2):157–166. doi:10.3904/kjim.2022.271.
18. Kittleson MM, Benjamin EJ, Blumer V, et al. 2025 ACC scientific statement on the management of obesity in adults with heart failure. J Am Coll Cardiol. 2025. doi:10.1016/j.jacc.2025.05.008.
19. Kittleson MM, Panjrath GS, Bates K, et al. Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway. J Am Coll Cardiol. 2026. doi: 10.1016/j.jacc. 2026.06.018. PMID: 42494134.
20. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–1084. doi:10.1056/NEJMoa230 6963. PMID: 37622681.
21. Kosiborod MN, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29(9):2358–2365. doi:10.1038/s41591-023-02526-x. PMID: 37635157.
22. Kosiborod MN, et al. Effects of semaglutide on symptoms, function, and quality of life in patients with heart failure with preserved ejection fraction and obesity: a prespecified analysis of the STEP-HFpEF trial. Circulation. 2024;149(3):204–216. doi: 10.1161/CIRCULATIONAHA.123.067505.
23. Kosiborod MN, Petrie MC, Borlaug BA, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390 (15):1394–1407. doi:10.1056/NEJMoa2313917. PM ID: 38587233.
24. Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949–961. doi:10.1016 /S0140-6736(24)01643-X. PMID: 39222642.
25. Kramer CM, Borlaug BA, Zile MR, et al. Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy. J Am Coll Cardiol. 2025;85(7):699–706. doi: 10.1016/j.jacc.2024.11.001. PMID: 39566869.
26. McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627–3639. doi:10.1093/eurheartj/ehad195. PMID: 37622666.
27. Monzo L, Savarese G, Mullens W, et al. Pharmacological treatment for patients with obesity and heart failure: focus on glucagon-like peptide-1 receptor agonists. European Journal of Heart Failure expert consensus document. Eur J Heart Fail. 2025; 27(11):2465–2479. doi:10.1002/ejhf.70082. PMID: 41309245.
28. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10 431):1027–1050. doi:10.1016/S0140-6736(23)027 50-2. PMID: 38432237.
29. Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393(24):2409–2420. doi:10. 1056/NEJMoa2505928. PMID: 41406444.
30. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427–437. doi:10.1056/NEJMoa2410027. PMID: 395558 26.
31. Packer M, Zile MR, Kramer CM, Murakami M, Ou Y, Borlaug BA. Interplay of chronic kidney disease and the effects of tirzepatide in patients with heart failure, preserved ejection fraction, and obesity: the SUMMIT trial. J Am Coll Cardiol. 2025; 85(18):1721–1735. doi: 10.1016/j.jacc.2025.03.009. PMID: 40162940.
32. Packer M, Zile MR, Kramer CM, et al. Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis. J Am Coll Cardiol. 2025;86(10):696–707. doi: 10.1016/j.jacc.2025.06.058. PMID: 4090 3131.
33. Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2022;118(17):3272–3287. doi:10.1093/cvr/cvac013.
34. Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9:e11. doi:10. 15420/cfr.2023.05. PMID: 37547123.
35. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022; 387(12):1089–1098. doi:10.1056/NEJMoa2206286.
36. Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475–1485. doi:10.1056/NEJMoa240 7107.
37. Taktaz F, Fontanella RA, Scisciola L, et al. Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide. Cardiovasc Diabetol. 2024. doi:10.11 86/s12933-024-02319-7.
38. Toshpulatov, S. S., Abdubannoyeva, N. A., Zayliddinova, K. Q., & Aliyev Sh, A. (2026). Surunkali stress va oksidativ shikastlanish sharoitida yurak to ‘qimalarining morfofunksional va immunogisto-kimyoviy o ‘zgarishlari (adabiyotlar sharhi). Медицинский журнал молодых ученых, (18 (06)), 209-213.
39. Verma S, et al. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024;45(35):3254–3269. doi:10.1093/eurheartj/ehae322.
40. Wang L, et al. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025. doi:10.1001 /jamanetworkopen.2025.26327. PMID: 40788646.
41. Zile MR, Borlaug BA, Kramer CM, et al. Effects of tirzepatide on the clinical trajectory of patients with heart failure, preserved ejection fraction, and obesity. Circulation. 2025;151(10):656–668. doi:10.1161/CIRCULATIONAHA.124.072679. PMID: 39556714.